Market Newsdesk

MITCHEL FIELD, N.Y., Dec. 03, 2020 (GLOBE NEWSWIRE) — Frequency Electronics, Inc. (“FEI” or the “Company”) (NASDAQ-FEIM) is pleased to announce the award of a contract for precision Voltage Controlled Quartz Crystal Oscillators (VCXO) with a contract value of approximately $5.2m. This is a follow-on to a contract previously awarded and announced in September 2019. The oscillators will provide critical timing information for US Government satellites.

FEI CEO Stan Sloane commented, “We are extremely pleased that additional VCXOs have been selected for this critical satellite program. As we stated in our September 3, 2019 press release, we anticipated additional orders for these oscillators and this award validates that prediction. We anticipate additional orders in addition to this one, as well. We are also proud to continue our legacy of providing critical components for key US Government programs that support our warfighters and our allies.”

About Frequency Electronics

Frequency Electronics, Inc. is a world leader in the design, development and manufacture of high precision timing, frequency generation and RF control products for space and terrestrial applications. FEI’s products are used in satellite payloads and in other commercial, government and military systems including C4ISR and electronic warfare, missiles, UAVs, aircraft, GPS, secure communications, energy exploration and wireline and wireless networks. Frequency has received over 100 awards of excellence for achievements in providing high performance electronic assemblies for over 150 space and DOD programs. The Company invests significant resources in research and development to expand its capabilities and markets.

Frequency’s Mission Statement: “Our mission is to provide precision time and low phase noise frequency generation systems from 1 Hz to 50 GHz, for space and other challenging environments.”

Subsidiaries and Affiliates: FEI-Zyfer provides GPS and secure timing (“SAASM”) capabilities for critical military and commercial applications; FEI-Elcom Tech provides Electronic Warfare (“EW”) sub-systems and state-of-the-art RF microwave products. Additional information is available on the Company’s website: www.frequencyelectronics.com

Contact information: Stanton Sloane, President & Chief Executive Officer; Steven
Bernstein, Chief Financial Officer;
  
TELEPHONE: (516) 794-4500 ext.5000 WEBSITE: www.freqelec.com

 

LYON, France and CAMBRIDGE, Mass., Dec. 03, 2020 (GLOBE NEWSWIRE) — ERYTECH Pharma (Nasdaq & Euronext: ERYP),a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announcesa webcast scheduled for investors to discuss the results from the NOPHO sponsored Phase 2 trial of eryaspase in ALL patients.

The data will be presented by Dr. Line Stensig Lynggaard at the 62^nd American Society of Hematology (ASH) Annual Meeting. On the webcast, Dr. Birgitte Klug Albertsen, Associate Professor at Aarhus University Hospital, Denmark, and Principal Investigator of the trial, will comment on the data and be available for Q&A.

O
ral
P
resentation
Details
(accessible only if registered for the ASH annual meeting)

Abstract #467: NOR-GRASPALL 2016 (NCT03267030): Asparaginase encapsulated in Erythrocytes(eryaspase) – a promising alternative to PEG-asparaginase in case of hypersensitivity

The NOR-GRASPALL-2016 trial evaluated the safety and pharmacological profile of eryaspase in ALL patients who developed hypersensitivity reactions to pegylated asparaginase. The trial was conducted at 21 clinical sites in the Nordic and Baltic countries of Europe and enrolled 55 patients. The study findings will be featured as an oral presentation at ASH by Dr. Line Stensig Lynggaard, representing NOPHO, on 6th December 2020 2.45pm PST/ 5.45pm EST / 11.45pm CET. Final results from this trial will be presented at the meeting.

The abstract can be found on-line at: https://ash.confex.com/ash/2020/webprogram/Paper139373.html

Webcast
Details

ERYTECH will hold a webcast on Monday, December 7, at 4:00 pm CET / 10:00am ET.

Dr. Birgitte Klug Albertsen, Associate Professor at Aarhus University Hospital, Denmark, and Principal Investigator of the trial, Dr. Iman El-Hariry, Chief Medical Officier of ERYTECH Pharma, and Gil Beyen, Chief Executive Officer of ERYTECH Pharma, will comment on the data and be available for Q&A.

The webcast can be followed live online via the link: https://edge.media-server.com/mmc/p/yp9nynh6.

Conference ID#: 2272914#

About Acute Lymphoblastic Leukemia

Acute lymphoblastic leukemia (ALL) is a cancer of the blood and bone marrow that is the most common type of cancer in children in the US and Europe. More than 13,000 cases are diagnosed in the US and Europe each year with the majority of patients diagnosed before age 20. Asparaginase has been an integral component of ALL treatment for several years but is associated with treatment-limiting hypersensitivity in up to 30% of patients. Discontinuation of asparaginase therapy in ALL patients has been associated with inferior event free survival highlighting the need for additional asparaginase based treatment options.

About ERYTECH and eryaspase

ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS^® platform, which uses a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates for patients with high unmet medical needs. ERYTECH’s primary focus is on the development of product candidates that target the altered metabolism of cancer cells by depriving them of amino acids necessary for their growth and survival.

The Company’s lead product candidate, eryaspase, which consists of L-asparaginase encapsulated inside donor-derived red blood cells, targets the cancer cell’s altered asparagine and glutamine metabolism. Eryaspase is in Phase 3 clinical development for the treatment of second-line pancreatic cancer and in Phase 2 for the treatment of first-line triple-negative breast cancer. An investigator-sponsored Phase 2 study in acute lymphoblastic leukemia was recently completed in the Nordic countries of Europe. Eryaspase is not approved in any country.

ERYTECH produces its product candidates for treatment of patients in Europe at its GMP-approved manufacturing site in Lyon, France, and for patients in the United States at its GMP manufacturing site in Princeton, New Jersey, USA.

ERYTECH is listed on the Nasdaq Global Select Market in the United States (ticker: ERYP) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: ERYP). ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable,
EnterNext
PEA-PME 150 and Next Biotech indexes. 

For more information, please visit

www.erytech.com
        

Forward-looking information

This press release contains forward-looking statements including but not limited to statements with respect to the clinical development plans of eryaspase; the potential indications for and benefits of eryaspase; statements relating to the TRYbeCA-1 clinical trial, including the timeline for patient enrollment as well as expected timing of the availability of results and interim superiority analysis; potential impacts on the Company’s clinical trials, including TRYbeCA-1 clinical trial, due to the coronavirus (COVID-19) pandemic such as delays in regulatory review, manufacturing and supply chain interruptions; and the overall impact of the COVID-19 pandemic on the global healthcare system as well as the Company’s business, financial condition and results of operations. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will” and “continue” and similar expressions. Such statements, forecasts and estimates are based on various assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable when made but may or may not prove to be correct. Actual events are difficult to predict and may depend upon factors that are beyond ERYTECH’s control. There can be no guarantees with respect to pipeline product candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. Therefore, actual results and timeline may turn out to be materially different from the anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Further description of these risks, uncertainties and other risks can be found in the Company’s regulatory filings with the French Autorité des Marchés Financiers (AMF), the Company’s Securities and Exchange Commission (SEC) filings and reports, including in the Company’s 2019 Document d’Enregistrement Universel filed with the AMF on March 18, 2020 and in the Company’s Annual Report on Form 20-F filed with the SEC on March 18, 2020 and future filings and reports by the Company. Given these uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of this press release. Readers are cautioned not to place undue reliance on any of these forward-looking statements. ERYTECH disclaims any obligation to update any such forward-looking statement, forecast or estimates to reflect any change in ERYTECH’s expectations with regard thereto, or any change in events, conditions or circumstances on which any such statement, forecast or estimate is based, except to the extent required by law. In addition, the COVID-19 pandemic and the associated containment efforts have had a serious adverse impact on the economy, the severity and duration of which are uncertain. Government stabilization efforts will only partially mitigate the consequences. The extent and duration of the impact on the Company’s business and operations is highly uncertain, and that impact includes effects on its clinical trial operations and supply chain. Factors that will influence the impact on the Company’s business and operations include the duration and extent of the pandemic, the extent of imposed or recommended containment and mitigation measures, and the general economic consequences of the pandemic. The pandemic could have a material adverse impact on the Company’s business, operations and financial results for an extended period of time.

CONTACTS

ERYTECH                      Eric Soyer CFO & COO	LifeSci Advisors, LLC Investor Relations Corey Davis, Ph.D.	NewCap Mathilde Bohin / Louis-Victor Delouvrier Investor relations Nicolas Merigeau Media relations
+33 4 78 74 44 38 [email protected]	+1 (212) 915 – 2577 [email protected]	+33 1 44 71 94 94 [email protected]

PDF available at: http://ml.globenewswire.com/Resource/Download/a076b04e-4b8a-4e48-88e7-06570c97b315

SANTA CLARA, Calif., Dec. 03, 2020 (GLOBE NEWSWIRE) — Applied Materials, Inc. today announced that its Board of Directors has approved a quarterly cash dividend of $0.22 per share payable on the company’s common stock. The dividend is payable on March 18, 2021 to shareholders of record as of Feb. 25, 2021.

About Applied Materials

Applied Materials, Inc. (Nasdaq: AMAT) is the leader in materials engineering solutions used to produce virtually every new chip and advanced display in the world. Our expertise in modifying materials at atomic levels and on an industrial scale enables customers to transform possibilities into reality. At Applied Materials, our innovations make possible the technology shaping the future. Learn more at www.appliedmaterials.com.

Contact:


Ricky Gradwohl
(editorial/media) 408.235.4676
Michael Sullivan (financial community) 408.986.7977

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/

TORONTO, Dec. 03, 2020 (GLOBE NEWSWIRE) — Caldas Gold Corp. (TSX-V: CGC; OTCQX: ALLXF) (“Caldas Gold” or “the Company”) has completed the non-brokered private placement with a group of investors principally referred by Aris Gold Corporation (“Aris Gold”) for aggregate gross proceeds of C$85 million (the “Offering”). The terms of the Offering and proposed Board, management and name changes were announced by way of news release on November 23, 2020.

The C$85 million has been deposited in escrow pending the satisfaction of certain release conditions on or before March 31, 2021, or as may be extended. The net proceeds are expected to be used for the modernization and expansion of the Caldas Gold mining operations in Colombia and for working capital purposes. The primary release conditions are listed below and are expected to be satisfied by mid-January 2021:

• the Company shall have obtained an extension for the mining contribution/concession contract located within the mining license area referred to as Zona Baja for an additional minimum period of 20 years,
• the required steps are taken to reorganize the Board of the Company, as described below,
• all required steps are taken to change the name of the Company to “Aris Gold Corporation”, and
• the investor agreement between the Company and Gran Colombia Gold Corp. (“Gran Colombia”) remains in full force and affect, unamended.

The investor agreement provides that so long as Gran Colombia owns more than 20% of the Company, (i) Gran Colombia has the right to nominate two directors to the Board, (ii) Gran Colombia is required to vote in accordance with the recommendations of the Board or management of the Company, with certain exceptions, and (iii) Gran Colombia has the right to maintain its equity interest in the Company if new equity securities are issued in connection with a future financing or non-cash transaction. In addition, Gran Colombia has agreed to not sell any of its Caldas Gold equity securities (common shares and warrants) without prior consent from the Company for a period of two years.

Please see the Company’s news release dated November 23, 2020 for a description of all of the release conditions.

The new Board of the Company will consist of the following individuals (the “New Board”):

Ian Telfer	Chair, independent; newly nominated
David Garofalo	Independent; newly nominated
Peter Marrone	Independent; newly nominated
Daniela Cambone	Independent; newly nominated
Neil Woodyer	Non-independent; newly nominated
Attie Roux	Non-independent; newly nominated
Serafino Iacono	Non-independent; current Caldas Gold board member, Gran Colombia nominee
Hernan Martinez	Independent; current Caldas Gold board member, Gran Colombia nominee

The New Board will be supported by Frank Giustra, a mining financier and philanthropist who will act as a strategic advisor to the Company.

Following the constitution of the New Board, it is proposed that Neil Woodyer be appointed as Chief Executive Officer of the Company and lead a new management team based in Vancouver, British Columbia. These management changes will also be effected at the time of the satisfaction of the release conditions.

Neil Woodyer, CEO of Aris Gold, commented: “Completing this equity financing is our first exciting milestone toward building Aris Gold into an Americas-focused precious metals producer. We are working closely with the Caldas Gold team on plans for advancing the Caldas mine expansion project, which includes the development of the Deeps Zone mineralization and construction of a new 4,000 tpd processing facility to significantly increase gold production rates. We are also collaborating on workforce training initiatives and implementation of an industry-leading sustainability program. We expect to facilitate a seamless Board and management transition by early 2021.”

The securities issued or issuable pursuant to the Offering will be subject to a statutory hold period under applicable Canadian securities laws expiring on April 4, 2021.

Interest of Gran Colombia

Prior to the completion of the Offering, Gran Colombia owned, directly or indirectly, or exercised control or direction over, 53,435,989 common shares of Caldas Gold representing approximately 53.5% of the issued and outstanding common shares prior to the Offering, as well as 18,388,889 share purchase warrants entitling Gran Colombia to acquire one Caldas Gold common share at either C$2.75 or C$3.00.

Gran Colombia participated in the Offering for C$17 million to acquire 7,555,556 subscription receipts. Upon the conversion to common shares and warrants of all 37,777,778 subscription receipts issued in connection with the Offering, Caldas Gold will have 137,577,940 common shares issued and outstanding, of which Gran Colombia will hold 60,991,545 or 44.3%, on an undiluted basis. 

About Caldas Gold

Caldas Gold is a Canadian junior mining company currently advancing a major expansion and modernization of its underground mining operations at its Marmato Project in the Department of Caldas, Colombia. Caldas Gold also owns 100% of the Juby project, an advanced exploration stage gold project located within the Shining Tree area in the southern part of the Abitibi greenstone belt about 100 km south-southeast of the Timmins, Ontario gold camp.

Additional information on Caldas Gold can be found at www.caldasgold.ca and www.sedar.com.

Forward-Looking Information

This news release contains “forward-looking information” within the meaning of applicable Canadian securities legislation concerning the business, operations and financial performance of Caldas Gold. Forward-looking statements in this news release, which are all statements other than statements of historical fact, include, but are not limited to, statement relating to the satisfaction of the release conditions relating to the Offering; the intended use of net proceed of the Offering; the conversion of the subscription receipts and issuances of the underlying common shares and warrants; the changes to the board of directors and management of the Company; and the development of the MDZ
and construction of a new 4,000 tpd processing facility to significantly increase gold production rates. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, or “believes” or variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Caldas Gold to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements include: risks associated with receiving final regulatory and other approvals or consents, and the other risk factors as described under the caption “Risk Factors” in the Company’s annual information form dated August 17, 2020, which is available for view on SEDAR at


www.sedar.com


. Forward-looking statements contained herein are made as of the date of this news release and Caldas Gold disclaims, other than as required by law, any obligation to update any forward-looking statements whether as a result of new information, results, future events, circumstances, or if management’s estimates or opinions should change, or otherwise. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, the reader is cautioned not to place undue reliance on forward-looking statements.

For Further Information, Contact:

Mike Davies
Chief Financial Officer
(416) 360-4653
[email protected]

This announcement does not constitute an offer of securities for sale in the United States, nor may any securities referred to herein be offered or sold in the United States absent registration or an exemption from registration as provided in the U.S. Securities Act of 1933 as amended (the “Securities Act”) and the rules and regulations thereunder. The securities referred to herein have not been registered pursuant to the Securities Act and there is no intention to register any of the securities in the United States or to conduct a public offering of securities in the United States.

Neither the TSX-V nor its Regulation Services Provider (as that term is defined in the policies of the TSX-V) accepts responsibility for the adequacy or accuracy of this release.

HOUSTON, Dec. 03, 2020 (GLOBE NEWSWIRE) — Targa Resources Corp. (NYSE: TRGP) (“Targa” or the “Company”) announced today that representatives from the Company will participate in investor meetings at the Wells Fargo Virtual Midstream and Utility Symposium via video conference on Tuesday, December 8, 2020.

A copy of the slides used for the conference meetings will be available in the Investors section of the Company’s website at www.targaresources.com, or by going to https://www.targaresources.com/investors/events.

About Targa Resources Corp.

Targa Resources Corp. is a leading provider of midstream services and is one of the largest independent midstream infrastructure companies in North America. The Company owns, operates, acquires and develops a diversified portfolio of complementary midstream infrastructure assets. The Company is primarily engaged in the business of: gathering, compressing, treating, processing, transporting and purchasing and selling natural gas; transporting, storing, fractionating, treating and purchasing and selling NGLs and NGL products, including services to LPG exporters; and gathering, storing, terminaling and purchasing and selling crude oil.

For more information, please visit the Company’s website at www.targaresources.com.

Forward-Looking Statements

Certain statements in this release are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, included in this release that address activities, events or developments that the Company expects, believes or anticipates will or may occur in the future, are forward-looking statements. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of uncertainties, factors and risks, many of which are outside the Company’s control, which could cause results to differ materially from those expected by management of the Company. Such risks and uncertainties include, but are not limited to, weather, political, economic and market conditions, including a decline in the price and market demand for natural gas, natural gas liquids and crude oil, the impact of pandemics such as COVID-19, actions by the Organization of the Petroleum Exporting Countries (“OPEC”) and non-OPEC oil producing countries, the timing and success of business development efforts, and other uncertainties. These and other applicable uncertainties, factors and risks are described more fully in the Company’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2019, and any subsequently filed Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company does not undertake an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Contact the Company’s investor relations department by email at [email protected] or by phone at (713) 584-1133.

Sanjay Lad
Vice President, Finance & Investor Relations

Jennifer Kneale
Chief Financial Officer

CALABASAS, Calif., Dec. 03, 2020 (GLOBE NEWSWIRE) — StereoVision Imaging, Inc. (SVI) has been granted four new continuation patents by the United States Patent and Trademark Office (USPTO) and one new continuation patent issued by the European Patent Office. The patents build and expand upon the company’s extensive patent portfolio focused on biometric/object recognition and remote sensing technology.

The result of more than $100 million invested in R&D over the last 10 years, the new issuances bring SVI’s patent portfolio to 61 patents issued worldwide, with 46 patents pending across 24 patent families. They provide further protection for SVI’s Mil-Spec, field-proven and uniquely capable technology as it launches a new commercialization campaign.

“These new patents both continue and broaden the protection of our technology portfolio focused on detecting and measuring moving objects in real world situations,” commented SVI president, Gregory Steinthal. “These latest patents include changes that greatly expand the scope of the protections compared to the original related patents. They place SVI in an exceptionally secure position as we commercialize our IP portfolio of over 100 patents and patents pending, which includes potentially partnering with those who are infringing.”

“There have been a number of major investments or IPOs announced recently at multimillion to multibillion-dollar valuations, particularly in the autonomous and semi-autonomous vehicle space, involving the use of coherent FMCW LiDAR,” continued Steinthal. “As the owner of the first patents in the dual chirp 4D FMCW LiDAR space, we believe that we have established the furthest reaching IP portfolio for determining range and velocity, and we plan on exploiting this advantage fully.”

The new patents primarily relate to the application of frequency modulated continuous wave (FMCW) LiDAR technology that can be used for biometric measurement, identification and security, as well as other fields of use, such as autonomous vehicles, medical biometric monitoring, robotics, and mobile devices.

The five new patents cover a range of applications and benefits across several of the company’s 26 patent families:

Dual Chirp FMCW LiDAR (U.S. patent no. 10,578,738): Covers a laser-based radar system that uses two or more laser beams to improve speed and accuracy when determining the range and velocity of a distant target. It supports instantaneous per pixel velocity measurement and multibeam LiDAR applications by modulating the beam or “chirping” in a unique fashion using two or more chirps to accurately measure the Doppler shift or changes in the frequency of the beam reflected off a target that are caused by the target in motion.

Video Stream Improvements (patent no. 10,796,417): Using change detection between video frames, improvements are made to a video stream resulting in more accurate facial matching.

Eye
T
racking (U.S. patent no. 10,791,925): Using the position information of the face as provided by detection and ranging systems, such as by radar or LiDAR, eyeball detection and motion tracking information is determined.

Determining Range
Through Transparent Surfaces Such
as
G
lass (U.S. patent no. 10,761,210): Supports determining the distance to an object even through transparent surfaces, such as glass windows or vehicle windshields.

Fusion of FMCW LiDAR with Video (European patent no. 2399150B): A system that uses range and Doppler velocity from LiDAR along with images from video to estimate the six degree-of-freedom trajectory of a target.

SVI’s technology is currently in use globally for biometric facial recognition in military applications. Having now established an extensive portfolio of patent-protected IP around FMCW LiDAR, the company sees a “blue ocean” of potential commercial sector uses, including autonomous vehicles, industrial metrology, and any application where instantaneous, sub-millimeter accurate measurements of the size, distance and movement of objects, even at long ranges, are required. The company is now focused on commercializing its IP in these additional potentially highly lucrative markets.

For more than the last 10 years, SVI has been operating under a stealth U.S. military-funded facial recognition project. It has become the sole-source supplier to the U.S. Army of an advanced Facial Recognition Binocular System (FRBS) used by U.S. war fighters in the field. The company recently announced a new follow-on order that brought the total value of units purchased by the military to more than $4.5 million.

Since SVI was granted a commercial export license by the U.S. Commerce Department, the company has initiated the development of products for use in the commercial sector and has signed a number of IP licenses with strategic partners.

“In addition to introducing our own products, we look forward to entering into additional strategic licensing agreements to develop our dual chirp 4D FMCW LiDAR to its fullest commercial potential,” added Steinthal. “Our full family of LiDAR technology IP presents an attractive licensing opportunity to potential partners and supports our recently launched commercial product roll-out.”

SVI has conducted an extensive ‘Freedom to Operate’ (FTO) analysis of its Dual Chirp FMCW LiDAR patent family. Typically a lengthy and expensive process, especially for large patent portfolios, an FTO analysis determines whether a technology of interest infringes any patent owned by another party. It helps to mitigate the risk of potentially infringing on third-party patents when going to market, as well as helps identify potential infringement by others. It also facilitates product development by informing design changes necessary to avoid identified patent barriers. This helps to provide assurances to current and potential IP licensee and strategic partners.

The SVI Advantage

The main advantages of SVI’s dual chirp FMCW 4D LiDAR over other types of LiDAR is its ability to instantly determine at exceptionally long ranges all four key dimensions of an object: length, width, depth and velocity. Unique to SVI technology is its ability to acquire velocity or motion information instantaneously at 40x the distance compared to traditional systems, while still being eye safe.

SVI FMCW 4D LiDAR also works in real world situations regardless of a subject’s movement, pose, expression, lighting conditions or occlusions, such as beards or sunglasses, or through a vehicle windshield. The technology can measure velocity down to millimeters per second, allowing the remote detection of heart and breathing rate and speech (U.S. patent no. 9,872,639), as well as eye movement (U.S. patent no. 10,791,925), which can provide indications of alertness, psychological condition, or intent. The technology is also ideal for any application requiring highly accurate, sub-millimeter measurement of the size, distance and movement of any object, such as required for industrial metrology. To learn more, visit www.stereovisioninc.com.

About Ster
e
oVision Imaging

StereoVision Imaging, Inc. (SVI) is an emerging world leader in facial/object recognition and remote sensing technology for several markets and industries, from military reconnaissance and physical security to autonomous driving, robotics, mobile devices and more. For these applications, SVI develops and manufactures proprietary and highly advanced 4D FMCW LiDAR technology (four-dimensional frequency-modulated continuous wave light detection and ranging). The result of more than $100 million invested in R&D over the last 10 years, SVI’s Mil-Spec, field-proven and uniquely capable technology is protected by more than 100 patents and patents pending worldwide. For additional information, please visit www.stereovisioninc.com.

Company Contact

Tom Hallman, Director of Business Development
Tel (747) 207-9586
[email protected]

Investor & Media Relations Contact

Ron Both or Grant Stude
CMA Investor Relations
Tel (949) 432-7566
Email Contact

CAMBRIDGE, Mass., Dec. 03, 2020 (GLOBE NEWSWIRE) — CarGurus, Inc. (Nasdaq: CARG), a leading global, online automotive marketplace, today announced that Jason Trevisan, Chief Financial Officer and President, International, is scheduled to present at the Raymond James Technology Investors Conference at 2:20 PM ET on December 8, 2020.

A live webcast of the presentation will be accessible from the Investor Relations page of the company’s website at https://investors.cargurus.com.

About CarGurus

Founded in 2006, CarGurus (Nasdaq: CARG) is a global, online automotive marketplace connecting buyers and sellers of new and used cars. The Company uses proprietary technology, search algorithms and data analytics to bring trust and transparency to the automotive search experience and help users find great deals from top-rated dealers. CarGurus is the most visited automotive shopping site in the U.S. (source: Comscore Media Metrix^® Multi-Platform, Automotive – Information/Resources, Total Audience, Q3 2020, U.S. (Competitive set includes: CarGurus.com, Autotrader.com, Cars.com, TrueCar.com)). In addition to the United States, CarGurus operates online marketplaces in Canada and the United Kingdom. In the United States and the United Kingdom, CarGurus also operates the Autolist and PistonHeads online marketplaces, respectively, as independent brands.

To learn more about CarGurus, visit www.cargurus.com. CarGurus^® is a registered trademark of CarGurus, Inc.

© 2020 CarGurus, Inc., All Rights Reserved.

Contact:
Scot Fredo
[email protected]

 

Hong Kong, Dec. 03, 2020 (GLOBE NEWSWIRE) — Bridgetown Holdings Limited (the “Company”) announced today that, commencing December 7, 2020, holders of the 59,499,351 units sold in the Company’s initial public offering may elect to separately trade the Company’s Class A ordinary shares and warrants included in the units. Class A ordinary shares and warrants that are separated will trade on the Nasdaq Stock Market LLC under the symbols “BTWN” and “BTWNW,” respectively. No fractional warrants will be issued upon separation of the units and only whole warrants will trade. Those units not separated will continue to trade on the Nasdaq Stock Market LLC under the symbol “BTWNU.” Holders of units will need to have their brokers contact Continental Stock Transfer & Trust Company, the Company’s transfer agent, in order to separate the units into Class A ordinary shares and warrants.

Bridgetown Holdings Limited is a blank check company incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. While the Company may pursue a business combination target in any business or industry, the Company intends to focus on a target with operations or prospective operations in the technology, financial services, or media sectors in Southeast Asia. The Company is led by Chief Executive Officer and Chief Financial Officer, Daniel Wong, and Chairman Matt Danzeisen.

The units were initially offered by the Company in an underwritten offering. UBS Investment Bank and BTIG, LLC acted as the joint-book running managers for the offering. A registration statement relating to these securities has been filed with, and declared effective by, the Securities and Exchange Commission (“SEC”) on October 15, 2020. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Cautionary Note Concerning Forward-Looking Statements

This press release contains statements that constitute “forward-looking statements.” Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company’s registration statement and prospectus for the offering filed with the SEC. Copies are available on the SEC’s website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Contact

Karin Wong
+852-9755-6265
[email protected]

San Francisco, CA, Dec. 03, 2020 (GLOBE NEWSWIRE) — Aptology, the leading people intelligence platform, announced today that Sankar Narayanan, former Senior Director of Software Development at Workday, has joined the company as the Vice President of Engineering.

“We’re excited to have such an innovative and seasoned leader join the team as we enter our next growth phase. Sankar will be instrumental in developing our people intelligence platform to further empower leaders to understand their workforces and deliver significant performance improvements through actionable analytics,” said Brad Benson, CTO of Aptology.

When asked why he joined Aptology, Sankar said: “This is a unique opportunity to impact the entire employee journey, from start to finish in a way that hasn’t been done before. I want to lead the charge in developing state-of-the art technology that helps people and creates a truly people-centric platform for real performance.”

Over the last 20 years, Sankar has developed a reputation for excellence in engineering and people-centric product development, leading award-winning teams at Workday, Taleo, and Infosys.

 

About Aptology

Performance is about people. What if you could get the right person in the right role? What if you could do it objectively and at scale? Meet the Aptology platform: understand which behaviors drive performance and get visibility into your people. Hire better, improve front line manager coaching and increase diversity. Learn more at www.aptology.com

Caroline Tien-Spalding
Aptology
4255456789
[email protected]